Summary
Ten chronic schizophrenic patients received α-methyldopa during 13 weeks, in doses up to 6 Gm/day. The patients were evaluated psychiatrically and, simultaneously, their urinary excretion of 5-hydroxyindoleacetic acid, tryptamine, and indoleacetic acid was determined. Two patients became psychotic, five others showed worsening of their condition, two patients remained unaffected, and one patient improved. Urinary 5-hydroxyindoleacetic acid was uniformly decreased in all patients. The amount of tryptamine excretion seemed to be correlated to the severity of the psychiatric changes. Urinary indoleacetic acid output generally followed the pattern of tryptamine excretion. These findings indicate that the blocking of serotonin synthesis by α-methyldopa is not accompanied by psychiatric improvement, and that high tryptamine levels, perhaps in combination with lowered serotonin tissue levels, appear to be a factor in the development of psychosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ashcroft, G. W., D. Eccleston, and T. B. B. Crawford: 5-Hydroxyindole metabolism in rat brain. A study of the intermediate metabolism, using the technique of tryptophan loading. J. Neurochem. 12, 483–503 (1965).
Banerjee, S., and P. S. Agarwal: Tryptophan-nicotinic acid metabolism in schizophrenia. Proc. Soc. exp. Biol. (N.Y.) 97, 657–659 (1958).
Benassi, C. A., P. Benassi, G. Allegri, and P. Ballarin: Tryptophan metabolism in schizophrenic patients. J. Neurochem. 7, 264–270 (1961).
Berlet, H. H., K. Matsumoto, G. R. Pscheidt, J. Spaide, C. Bull, and H. E. Himwich: Biochemical correlates of behavior in schizophrenic patients. Arch. gen. Psychiat. 13, 521–531 (1965).
Brodie, B. B., R. Kuntzman, C. W. Hirsch, and E. Costa: Effects of decarboxylase inhibition on the biosynthesis of brain monoamines. Life Sci. 3, 81–84 (1962).
Brune, C. C., and H. E. Himwich: Biogenic amines and behavior in schizophrenic patients. In: Recent advances in biological psychiatry. Vol. 5, pp. 144 to 160. New York: Plenum Press 1963.
—, and G. R. Pscheidt: Correlations between behavior and urinary excretion of indoleamines and catecholamines in schizophrenic patients as affected by drugs. Fed. Proc. 20, 889–893 (1961).
Coppen, A., D. M. Shaw, A. Malleson, E. Eccleston, and G. Gundy: Tryptamine metabolism in depression. Brit. J. Psychiat. 111, 993–998 (1965).
Degkwitz, R.: Was sagt die 5-Hydroxyindolessigsäure-Ausscheidung im Urin beim Menschen über den Serotoninstoffwechsel und die Wirksamkeit in diesen Stoffwechsel eingreifender Medikamente aus? Klin. Wschr. 43, 887–892 (1965).
Dewhurst, W. G., and E. Marley: Action of sympathomimetic and allied amines on the central nervous system of the chicken. Brit. J. Pharmacol. 25, 705–727 (1965).
Dollery, C. T.: Alpha-Methyldopa in the treatment of hypertension. Med. Clin. N. Amer. 48, 335–345 (1964).
Dubach, U. C.: Methyldopa and depression. Brit. med. J. 1963 I, 261.
Ernst, A. M., H. van Andel u. G. A. Charbon: Beruht die experimentelle Katatonie durch Tryptamin auf einer Verdrängung des 5-Hydroxytryptamin? Psychopharmacologia (Berl.) 2, 425–435 (1961).
Fullerton, A. G., and D. Morton-Jenkins: Methyldopa and depression. Brit. med. J. 1963 I., 538–539.
Gillespie, L., J. Oates, R. Crout, and A. Sjoerdsma: Clinical and chemical studies with α-methyl DOPA in patients with hypertension. Circulation 25, 281–291 (1962).
Hamilton, M., and H. Kopelman: Treatment of severe hypertension with methyldopa. Brit. med. J. 1963 I, 151–155.
Hess, S. M., and W. Doepfner: Behavioral effects and brain amine content in rats. Arch. int. Pharmacodyn. 134, 89–99 (1961).
Hodge, J. V., J. A. Oates, and A. Sjoerdsma: Reduction of central effects of tryptophan by a decarboxylase inhibitor. Clin. Pharmacol. Ther. 5, 149–155 (1964).
Horwitz, D., and A. Sjoerdsma: Use of two enzyme inhibitors in hypertension therapy. Postgrad. Med. 34, 140–144 (1963).
Keasling, H. H., R. R. Russell, and H. J. Triesenberg: The overt effects of tryptamine and their antagonism in the mouse. Fed. Proc. 22, 624 (1963).
Keup, W.: A standard method for the clinical evaluation of psychoactive drugs. Excerpta Med. Interntl. Congr. Series 150, 2017–2029 (1966).
Kopin, I. J.: Tryptophan loading and excretion of 5-hydroxy-indoleacetic acid in normal and schizophrenic subjects. Science 129, 835–836 (1959).
La Brosse, E. H., J. Kopin, W. R. Felix, and R. J. Westlake: Urinary tryptamine and indole-3-acetic acid excretion by schizophrenic patients. Use of tryptamine-indoleacetic acid ratio as index of monoamine oxidase inhibition. J. Psychiat. Res. 2, 185–197 (1964).
Ljungberg, E.: 5-Hydroxy-3-indoleacetic acid excretion in the urine, a specific diagnostic sign in fatal catatonia, pp. 169–170. In: The clinical chemistry of monamines. H. Varley, ed. New York: Elsevier Publ. 1963.
Mosher, L. R., G. L. Klerman, and J. F. Greaney: A clinical trial of α-methyldopa in elated states. Amer. J. Psychiat. 122, 1185–1188 (1966).
Oates, J. A., L. G. Gillespie, S. Udenfriend, and A. Sjoerdsma: Decarboxylase inhibition and blood pressure reduction by α-methyl-3,4-dihydroxy-D,L-phenylalanine. Science 131, 1890–1891 (1960).
Price, J. M., R. R. Brown, and H. A. Peters: Tryptophan metabolism in porphyria, schizophrenia, and a variety of neurologic and psychiatric diseases. Neurology (Minneap.) 9, 456–468 (1959).
Sharman, D. F.: Metabolism of tryptamine and related compounds in the central nervous system. Brit. med. Bull. 21, 62–65 (1965).
—, and S. E. Smith: The effect of α-methyldopa on the metabolism of 5-hydroxytryptamine in rat brain. J. Neurochem. 9, 403–406 (1962).
Shore, P. A.: The mechanism of norepinephrine depletion by reserpine, metaraminol, and related agents. The role of monoamine oxidase. Pharmacol. Rev. 18, 561–568 (1966).
Sjoerdsma, A.: α-Methyldopa, antihypertensive drug with an unusual mechanism of action. Heart Bull. 12, 1–4 (1963).
—, and S. Udenfriend: Identification and assay of urinary tryptamine: application as an index of monoamine oxidase inhibition in man. J. Pharmacol. exp. Ther. 126, 217–222 (1959).
— — — —: Serotonin synthesis in carcinoid patients: its inhibition by α-methyldopa, with measurement of associated increase of urinary 5-hydroxytryptophan. New Engl. J. Med. 263, 585–588 (1960).
Smirk, H.: Hypotensive action of methyldopa. Brit. med. J. 1963 I, 146–150.
Sourkes, T. L.: Dopa-decarboxylase: substrates, coenzymes, inhibitors. Pharmacol. Rev. 18, 53–60 (1966).
—, G. F. Murphy, and B. Chavez-Lara: A metabolic study of α-methyl-β-(3,4-dihydroxyphenyl)-D,L-alanine in man. J. med. pharm. Chem. 5, 204–210 (1962).
Sprince, H.: Indole metabolism in mental illness. Clin. Chem. 7, 207–229 (1961).
Tedeschi, D. H., R. E. Tedeschi, and E. J. Fellows: The effects of tryptamine on the central nervous system, including a pharmacological procedure for the evaluation of iproniazid-like drugs. J. Pharmacol. exp. Ther. 126, 223–232 (1959).
Udenfriend, S., E. Titus, and H. Weissbach: The identification of 5-hydroxy-3-indoleacetic acid in normal urine, and a method for its assay. J. biol. Chem. 216, 499–505 (1955).
Weissbach, H., W. King, A. Sjoerdsma, and S. Udenfriend: Formation of indole-3-acetic acid and tryptamine in animals. J. biol. Chem. 234, 81–86 (1959).
—, W. Lovenberg, B. G. Redfield, and S. Udenfriend: In vivo metabolism of serotonin and tryptamine; effect of monoamine oxidase inhibition. J. Pharmacol. exp. Ther. 131, 26–30 (1961).
Woolley, D. W.: The biochemical basis of psychosis, or, the serotonin hypothesis about mental diseases. New York-London: J. Wiley and Sons, Inc. 1962.
Zeller, E. A., J. Bernsohn, W. M. Inskip, and J. W. Lauer: On the effect of monoamine oxidase inhibition on behavior and tryptophan metabolism of schizophrenic patients. Naturwissenschaften 44, 427 (1957).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Herkert, E.E., Keup, W. Excretion patterns of tryptamine, indoleacetic acid, and 5-hydroxyindoleacetic acid, and their correlation with mental changes in schizophrenic patients under medication with alpha-methyldopa. Psychopharmacologia 15, 48–59 (1969). https://doi.org/10.1007/BF00410800
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00410800